AI医学成像初创公司AZmed获1500万欧元A轮融资
法国医疗科技初创公司AZmed宣布已获得1500万欧元的A轮融资，由Maison Worms、Techstars和Tempact Ventures领投。
AZmed开发了一款名为Rayvolve的人工智能（AI）软件，旨在为放射科医生和急诊医生提供诊断辅助。该软件可以识别标准放射照相中的各种异常情况，从而节省时间，提高检查解释的效率，并降低诊断错误的风险。
Rayvolve使用深度学习算法来分析医学图像，并自动检测可疑区域。该软件可以识别广泛的异常情况，包括肺结节、骨骼骨折和脑出血。
AZmed首席执行官兼联合创始人Pierre-Emmanuel Berthier表示：“我们很高兴获得这笔融资，这将使我们能够进一步开发Rayvolve并将其推向市场。我们相信，Rayvolve可以对医疗保健行业产生重大影响，通过帮助医生更准确、更有效地诊断疾病。”
Maison Worms投资经理Pierre-Antoine de Selancy表示：“我们对AZmed的团队和技术印象深刻。我们相信，Rayvolve具有成为医疗保健领域变革性工具的潜力。”
Techstars医疗保健加速器董事总经理Bill Evans表示：“我们很高兴支持AZmed。他们的团队拥有丰富的医疗保健和技术经验，他们正在解决医疗保健领域的一个重要问题。”
Tempact Ventures合伙人Peter van der Zanden表示：“我们相信，Rayvolve可以对患者护理产生重大影响。我们很高兴能够支持AZmed团队，帮助他们实现他们的愿景。”
AZmed计划利用这笔资金来扩大其团队、开发Rayvolve的新功能并与医院和诊所合作，以将其软件推向市场。
英语如下：
**Headline:** AI Medical Imaging Software Raises Multi-Million Euro Funding to Enhance DiagnosticEfficiency
**Keywords:** AI in Medicine, Funding, Diagnostic Assistance
**Article:**
AI medical imaging startup AZmed has raised €15 million in SeriesA funding led by Maison Worms, Techstars, and Tempact Ventures.
AZmed has developed an artificial intelligence (AI) software called Rayvolve that is designed to provide diagnostic assistance to radiologists and emergency physicians. The software can identify a wide range of abnormalities in standard radiographs, saving time, increasing the efficiencyof image interpretation, and reducing the risk of diagnostic errors.
Rayvolve uses deep learning algorithms to analyze medical images and automatically detect suspicious areas. The software can identify a wide range of abnormalities, including lung nodules, bone fractures, and brain bleeds.
“We are very pleased to have secured this funding, which will enable us to further develop Rayvolve and bring it to market,” said Pierre-Emmanuel Berthier, CEO and co-founder of AZmed. “We believe that Rayvolve has the potential to make a significant impact on the healthcare industry by helping clinicians diagnose diseases more accurately and efficiently.”
“We were impressed by theAZmed team and their technology,” said Pierre-Antoine de Selancy, investment manager at Maison Worms. “We believe that Rayvolve has the potential to be a transformative tool in healthcare.”
“We are excited to support AZmed,” said Bill Evans, managing director of Techstars Healthcare Accelerator. “Their team has deep healthcare and technology experience, and they are addressing an important unmet need in healthcare.”
“We believe that Rayvolve can have a major impact on patient care,” said Peter van der Zanden, partner at Tempact Ventures. “We are excited to support the AZmed team as they work to realize their vision.”
AZmed plans to use the funding to expand its team, develop new features for Rayvolve, and partner with hospitals and clinics to bring its software to market.
【来源】https://tech.eu/2024/02/20/french-medtech-azmed-raises-eur15m/
Views: 1